Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03313661

Enrollment

Registered

2017-10-18

Start date

2017-10-14

Completion date

2020-12-31

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

Evaluation of the glycemic efficacy of cabergoline on diabetic patients

Detailed description

Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long acting D2 agonist, is expected to play a role in the glycemic control.

Interventions

DRUGCabergoline

cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide

DRUGGliclazide

gliclazide (60-120 mg)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Diabetic patients.

Exclusion criteria

* Other drugs administration

Design outcomes

Primary

Measure	Time frame	Description
The level of fasting and post prandial BG level	4 months	Fasting and post prandial BG level will be measured after 4 months

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, consultant

Sheriefabdelsalam@yahoo.com00201095159522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026